Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06695845 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

A Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Jazz Pharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT06695845 is a Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 200 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06695845, a Phase 2 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Conditions Studied

Breast Cancer Non-Small Cell Lung Cancer Colorectal Cancer Ovarian Cancer Endometrial Cancer Gastric Cancer Esophageal Cancer Urothelial Carcinoma GastroEsophageal Cancer Salivary Gland Cancer

Interventions

  • DRUG Zanidatamab

Study Locations (20)

Florida

  • Florida Cancer Specialists - South - Fort Myers
  • Florida Cancer Specialists - Lake Nona - Orlando
  • Florida Cancer Specialists - North - St. Petersburg
  • Florida Cancer Specialists - East - West Palm Beach

Texas

  • Texas Oncology - West Texas - Amarillo
  • Texas Oncology - DFW - Dallas
  • MD Anderson Cancer Center - Houston
  • Texas Oncology - San Antonio - San Antonio

Seoul

  • Samsung Medical Center - Gangnam-gu
  • Seoul National University Hospital - Jongno-gu
  • Severance Hospital - Seodaemun-gu

Tennessee

  • Tennessee Cancer Specialists - Knoxville
  • SCRI Oncology Partners - Nashville

Arizona

  • Arizona Oncology Associates, PC - NAHOA - Prescott

Colorado

  • Rocky Mountain Cancer Center - Littleton

Illinois

  • Affiliated Oncologists - Chicago Ridge

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-01-14
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

Jazz Pharmaceuticals

128 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06695845

The ClinicalTrials.gov registry entry for NCT06695845 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Zanidatamab is the first listed.

NCT06695845 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Texas, Seoul.

Frequently Asked Questions

What is clinical trial NCT06695845 about?

NCT06695845 is a clinical study titled "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors". The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

What is the current status of trial NCT06695845?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-01-14. Estimated completion is 2027-12-31.

What conditions does trial NCT06695845 study?

This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer, Endometrial Cancer.

What interventions are being tested in trial NCT06695845?

The interventions under investigation include: Zanidatamab (DRUG).

Who is sponsoring clinical trial NCT06695845?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06695845 being conducted?

This trial has 20 study locations across Arizona, Colorado, Florida, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.